Reply by Authors.
Reply by Authors. J Urol. 2026 Aug 24; 101097JU0000000000005259.
PMID: 42635166
Reply by Authors.
Reply by Authors. J Urol. 2026 Aug 20; 101097JU0000000000005258.
PMID: 42623606
Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ ± Papillary Disease.
Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ ± Papillary Disease. J Urol. 2026 Jul 06; 101097JU0000000000005198.
PMID: 42406609
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer. Eur Urol Open Sci. 2026 Jul; 89:77-88.
PMID: 42325814
Clinical trials corner issue 12(1).
Clinical trials corner issue 12(1). Bladder Cancer. 2026 Jan-Mar; 12(1):23523735261424951.
PMID: 41768417
Clinical Trial Design for Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer-Single-Arm Design Was Necessary, Randomized Trials Are Now Essential.
Clinical Trial Design for Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer-Single-Arm Design Was Necessary, Randomized Trials Are Now Essential. J Urol. 2026 Jun; 215(6):659-660.
PMID: 41616256
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series.
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series. Urol Oncol. 2026 Mar; 44(3):110984.
PMID: 41529351
Reply by Authors.
Reply by Authors. J Urol. 2026 Jan; 215(1):52-53.
PMID: 41133766
Reply by Authors.
Reply by Authors. J Urol. 2026 Jan; 215(1):55-56.
PMID: 41091629
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer.
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer. J Urol. 2026 01; 215(1):44-56.
PMID: 40956664